Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer

National Medical Journal of China

Volumn 88, Issue 10, 2008, Pages 669-673

  Dai, Mei Jie ^a   Chen, Li Li ^a   Zheng, Yan Bo ^a   Chen, Wei ^a   Tao, Zhi Hua ^a   Weng, Zhi Liang ^a   Wu, Xiu Ling ^a   Li, Cheng Di ^a   Chen, Zhan Guo ^a   Chen, Xiao Dong ^a   Shi, Shao Bo ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

ETS; Gene fusion; Prostatic neoplasms; Reverse transcriptase polymerase chain reaction; TMPRSS2

Indexed keywords

ONCOPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS VARIANT 4; TRANSMEMBRANE PROTEASE SERINE 2;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DNA SEQUENCE; GENE FREQUENCY; GENE FUSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; BASE SEQUENCE; DNA, COMPLEMENTARY; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-ETS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SERINE ENDOPEPTIDASES;

EID: 44449098108     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Chinese source.
2. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 2005,310:644-648.
3. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res, 2006,66:3396-3400.
4. Soller MJ, Isaksson M, Elfving P, et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer, 2006,45:717-719.
5. Egevad L, Granfors T, Karlberg L, et al. Prognostic value of the Gleason score in prostate cancer. BJU Int, 2002,89:538-542.
6. Winnes M, Lissbrant E, Damber JE, et al. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep, 2007,17:1033-1036.
7. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene, 2007,26: 2667-2673.
8. Hermans KG, van Marion R, van Dekken H, et al. TMPRSS2: ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res, 2006,66:10658-10663.
9. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2: ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol, 2007,60: 1238-1243.
10. Tu JJ, Rohan S, Kao J, et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol, 2007,20:921-928.
11. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol, 2007,20: 467-473.
12. Chinese source.